Citadel Advisors LLC grew its stake in shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) by 92.7% during the second quarter, Holdings Channel reports. The institutional investor owned 126,784 shares of the medical equipment provider’s stock after purchasing an additional 60,991 shares during the quarter. Citadel Advisors LLC’s holdings in GenMark Diagnostics were worth $808,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. FMR LLC grew its stake in shares of GenMark Diagnostics by 0.5% during the second quarter. FMR LLC now owns 8,311,860 shares of the medical equipment provider’s stock valued at $53,030,000 after buying an additional 37,248 shares during the last quarter. BlackRock Inc. grew its stake in shares of GenMark Diagnostics by 8.1% during the second quarter. BlackRock Inc. now owns 3,358,717 shares of the medical equipment provider’s stock valued at $21,429,000 after buying an additional 250,306 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of GenMark Diagnostics by 18.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 274,850 shares of the medical equipment provider’s stock valued at $1,754,000 after buying an additional 42,122 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of GenMark Diagnostics by 10.7% during the second quarter. Russell Investments Group Ltd. now owns 172,512 shares of the medical equipment provider’s stock valued at $1,100,000 after buying an additional 16,611 shares during the last quarter. Finally, Donaldson Capital Management LLC grew its stake in shares of GenMark Diagnostics by 22.2% during the second quarter. Donaldson Capital Management LLC now owns 83,003 shares of the medical equipment provider’s stock valued at $530,000 after buying an additional 15,075 shares during the last quarter. 99.47% of the stock is currently owned by hedge funds and other institutional investors.

GenMark Diagnostics stock opened at $7.91 on Friday. The company has a quick ratio of 1.80, a current ratio of 2.04 and a debt-to-equity ratio of 0.19. The stock has a market cap of $447.14 million, a PE ratio of -6.54 and a beta of 0.90. GenMark Diagnostics, Inc has a 1-year low of $3.63 and a 1-year high of $9.93.

GenMark Diagnostics (NASDAQ:GNMK) last posted its earnings results on Monday, July 30th. The medical equipment provider reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.09). The firm had revenue of $14.94 million for the quarter, compared to analysts’ expectations of $14.74 million. GenMark Diagnostics had a negative return on equity of 87.96% and a negative net margin of 91.58%. sell-side analysts predict that GenMark Diagnostics, Inc will post -0.85 earnings per share for the current year.

In other news, CEO Hany Massarany sold 6,203 shares of the stock in a transaction dated Friday, August 24th. The shares were sold at an average price of $7.16, for a total transaction of $44,413.48. Following the completion of the sale, the chief executive officer now directly owns 682,491 shares in the company, valued at $4,886,635.56. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have sold 20,230 shares of company stock valued at $147,242. 7.50% of the stock is currently owned by company insiders.

A number of analysts have recently weighed in on the stock. BidaskClub upgraded shares of GenMark Diagnostics from a “hold” rating to a “buy” rating in a report on Friday, August 3rd. Canaccord Genuity increased their target price on shares of GenMark Diagnostics from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, June 29th. ValuEngine upgraded shares of GenMark Diagnostics from a “strong sell” rating to a “sell” rating in a report on Friday, August 10th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of GenMark Diagnostics in a report on Tuesday, July 31st. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $11.00.

About GenMark Diagnostics

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

See Also: What are the Benefits of Index Funds?

Want to see what other hedge funds are holding GNMK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GenMark Diagnostics, Inc (NASDAQ:GNMK).

Institutional Ownership by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.